تحميل...

A Phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

BACKGROUND: PARP-inhibitors and anti-angiogenics have activity in recurrent ovarian and breast cancer; however, the effect of combined therapy against PARP and angiogenesis in this population has not been reported. We investigated the toxicities and recommended phase 2 dosing (RP2D) of the combinati...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Liu, Joyce F., Tolaney, Sara M., Birrer, Michael, Fleming, Gini F., Buss, Mary K., Dahlberg, Suzanne E., Lee, Hang, Whalen, Christin, Tyburski, Karin, Winer, Eric, Ivy, Percy, Matulonis, Ursula A.
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	2013
الموضوعات:	Article
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3956307/ https://ncbi.nlm.nih.gov/pubmed/23810467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2013.05.020
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

A Phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

مواد مشابهة